BJH - volume 6, issue 1, march 2015
S. Meers MD, PhD, D. Breems MD, PhD, G. Bries MD, PhD, M. Delforge MD, PhD, C. Graux MD, PhD, D. Selleslag MD, L. Noens MD, PhD
The Belgian Hematological Society working group on myelodysplastic syndromes published their guidelines on the state of the art in diagnosis and treatment of myelodysplastic syndromes and the key points of these recommendations are presented in two issues of the Belgian Journal of Hematology.1 In this first paper we present the requirements for a correct diagnosis and classification of patients with myelodysplasia.
(BELG J HEMATOL 2015;6(1):10–5)
Read moreBJH - volume 6, issue Abstract Book BHS, january 2015
K. Vanhouteghem PharmD, B. Cauwelier MD, PhD, P. Costers , D. Selleslag MD, J. Emmerechts MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
D. Selleslag MD, C. Lambert MD, P. Zachée MD, PhD, D. Dierickx MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
E. Dumoulin PharmD, B. Depreter PharmD, L. Vanopdenbosch MD, J. Emmerechts MD, PhD, F. Nollet PhD, D. Selleslag MD, A. Van Hoof MD, PhD, J. Billiet MD
BJH - volume 5, issue Abstract Book BHS, january 2014
F. Nollet PhD, K. Boon , J. Emmerechts MD, PhD, S. Vermeire , R. D’Hondt , A. Van Hoof MD, PhD, D. Selleslag MD, J. Van Droogenbroeck MD, PhD, T. Lodewyck MD, J. Billiet MD
BJH - volume 5, issue Abstract Book BHS, january 2014
S. Meers MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD, C. Graux MD, PhD, G. Bries MD, PhD, D. Deeren , I. Vrelust MD, P. Pierre , C. Ravoet , K. Theunissen , F. Trullemans , L. Noens MD, PhD, P. Mineur MD
BJH - volume 4, issue 1, march 2013
A. Janssens MD, PhD, C. Lambert MD, G. Bries MD, PhD, A. Bosly MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD
The Belgian Hematological Society (BHS) guideline panel on adult primary immune thrombocytopenia (ITP) reviewed the recent literature on diagnosis and treatment to make recommendations on the best strategies for frontline and subsequent-line treatment. No treatment is necessary for patients with platelet counts higher than 30000/μl in the absence of bleeding symptoms. Patients newly diagnosed or relapsing after a long-term treatment-free period can be managed with corticosteroids with or without intravenous immunoglobulins. A second line therapy is indicated for those patients who are intolerant or unresponsive to or relapse after initial corticosteroid treatment and have a risk of bleeding. The guideline panel recommends splenectomy as it is the treatment with the highest curative potential and an acceptable safety profile. If possible, splenectomy should be delayed to at least twelve months after diagnosis as spontaneous remission can occur in this time period. Thrombopoietin receptor (TPO-R) agonists are recommended for patients who are refractory to or relapse after splenectomy or who have a contra-indication to splenectomy irrespective of the duration of ITP. The guideline panel agrees that rituximab, azathioprine, cyclophosphamide, cyclosporine A, danazol, dapsone, mycophenolate mofetil and vincristine/vinblastine are potential treatment options, especially for patients refractory to TPO-R agonists.
(BELG J HEMATOL 2013;1:11–20)
Read more
Top
